Akeso's (HKG:9926) board approved a plan for a trustee to buy back up to HK$200 million ordinary shares under a 2021 restricted share unit scheme, according to a Thursday Hong Kong bourse filing.
The shares will be repurchased from the open market, the drug company said.
Additionally, Chairperson and CEO Xia Yu, Chief Financial Officer Bing C. Wang, and three executive directors plan to increase their shareholdings in the company.
The parties will purchase a total of up to HK$50 million shares from the open market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments